CompletedPhase 2NCT05011851
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Studying Angelman syndrome due to a point mutation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neuren Pharmaceuticals Limited
- Principal Investigator
- James ShawNeuren Pharmaceuticals
- Intervention
- NNZ-2591(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 3-17 years · All sexes
- Timeline
- 2022 – 2024
Study locations (3)
- Sydney Children's Hospital, Randwick, New South Wales, Australia
- Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia
- Austin Health, Heidelberg, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05011851 on ClinicalTrials.govOther trials for Angelman syndrome due to a point mutation
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07417137A Natural History Study of Angelman SyndromeMassachusetts General Hospital
- RECRUITINGPHASE1, PHASE2NCT07181837A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman SyndromeMavriX Bio, LLC
- RECRUITINGPHASE2NCT07157254A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)Ultragenyx Pharmaceutical Inc
- RECRUITINGNCT06737718Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman SyndromeAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE3NCT06617429Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Ultragenyx Pharmaceutical Inc
- ENROLLING BY INVITATIONPHASE3NCT06415344Long-term Extension of GTX-102 in Angelman SyndromeUltragenyx Pharmaceutical Inc
- RECRUITINGPHASE1, PHASE2NCT05127226HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromeIonis Pharmaceuticals, Inc.
- RECRUITINGNCT06229769Natural History Study for Patients With Angelman SyndromeCentre Hospitalier Universitaire de Liege
See all trials for Angelman syndrome due to a point mutation →